| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
CymaBay Therapeutics Inc (NASDAQ: CBAY)
CBAY Technical Analysis
5
| As on 9th Jun 2023 CBAY STOCK Price closed @ 9.16 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.13 & Strong Buy for SHORT-TERM with Stoploss of 3.18 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CBAYSTOCK Price
| Open | 9.30 | Change | Price | % |
| High | 9.43 | 1 Day | -0.15 | -1.61 |
| Low | 9.10 | 1 Week | 0.18 | 2.00 |
| Close | 9.16 | 1 Month | -1.14 | -11.07 |
| Volume | 1091700 | 1 Year | 5.62 | 158.76 |
| 52 Week High 10.83 | 52 Week Low 1.72 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CBAY Daily Charts |
CBAY Intraday Charts |
Whats New @ Bazaartrend |
CBAY Free Analysis |
|
|
CBAY Important Levels Intraday
| RESISTANCE | 9.80 |
| RESISTANCE | 9.59 |
| RESISTANCE | 9.47 |
| RESISTANCE | 9.34 |
| SUPPORT | 8.98 |
| SUPPORT | 8.85 |
| SUPPORT | 8.73 |
| SUPPORT | 8.52 |
CBAY Forecast April 2024
| 4th UP Forecast | 10.64 |
| 3rd UP Forecast | 10.17 |
| 2nd UP Forecast | 9.87 |
| 1st UP Forecast | 9.58 |
| 1st DOWN Forecast | 8.74 |
| 2nd DOWN Forecast | 8.45 |
| 3rd DOWN Forecast | 8.15 |
| 4th DOWN Forecast | 7.68 |
CBAY Weekly Forecast
| 4th UP Forecast | 10.03 |
| 3rd UP Forecast | 9.75 |
| 2nd UP Forecast | 9.58 |
| 1st UP Forecast | 9.41 |
| 1st DOWN Forecast | 8.91 |
| 2nd DOWN Forecast | 8.74 |
| 3rd DOWN Forecast | 8.57 |
| 4th DOWN Forecast | 8.29 |
CBAY Forecast2024
| 4th UP Forecast | 27.56 |
| 3rd UP Forecast | 21.66 |
| 2nd UP Forecast | 18.01 |
| 1st UP Forecast | 14.36 |
| 1st DOWN Forecast | 3.96 |
| 2nd DOWN Forecast | 0.31 |
| 3rd DOWN Forecast | -3.34 |
| 4th DOWN Forecast | -9.24 |
CymaBay Therapeutics Inc ( NASDAQ USA Symbol : CBAY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CBAY Business Profile
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Address: 7575 Gateway Boulevard, Newark, CA, United States, 94560
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service